| Autor: |
Alex K, Bryant, Huiying, Yin, Matthew J, Schipper, Peter A, Paximadis, Thomas P, Boike, Derek P, Bergsma, Benjamin, Movsas, Robert T, Dess, Melissa A, Mietzel, Randi, Kendrick, Merita, Seferi, Michael M, Dominello, Martha M, Matuszak, Reshma, Jagsi, James A, Hayman, Lori J, Pierce, Shruti, Jolly |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
American journal of clinical oncology. 45(4) |
| ISSN: |
1537-453X |
| Popis: |
The addition of adjuvant durvalumab improves overall survival in locally advanced nonsmall-cell lung cancer (NSCLC) patients treated with definitive chemoradiation, but the real-world uptake of adjuvant durvalumab is unknown.We identified patients with stage III NSCLC treated with definitive concurrent chemoradiation from January 2018 to October 2020 from a statewide radiation oncology quality consortium, representing a mix of community (n=22 centers) and academic (n=5) across the state of Michigan. Use of adjuvant durvalumab was ascertained at the time of routine 3-month or 6-month follow-up after completion of chemoradiation.Of 421 patients with stage III NSCLC who completed chemoradiation, 322 (76.5%) initiated adjuvant durvalumab. The percentage of patients initiating adjuvant durvalumab increased over time from 66% early in the study period to 92% at the end of the study period. There was substantial heterogeneity by treatment center, ranging from 53% to 90%. In multivariable logistic regression, independent predictors of durvalumab initiation included more recent month (odds ratio [OR]: 1.05 per month, 95% confidence interval [CI]: 1.02-1.08, P=0.003), lower Eastern Cooperative Oncology Group score (OR: 4.02 for ECOG 0 vs. 2+, 95% CI: 1.67-9.64, P=0.002), and a trend toward significance for female sex (OR: 1.66, 95% CI: 0.98-2.82, P=0.06).Adjuvant durvalumab for stage III NSCLC treated with definitive chemoradiation was rapidly and successfully incorporated into clinical care across a range of community and academic settings in the state of Michigan, with over 90% of potentially eligible patients starting durvalumab in more recent months. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
